Clinical Trials Logo

Filter by:
NCT ID: NCT01951326 Completed - Crohn's Disease Clinical Trials

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

MAPUS
Start date: September 2013
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.

NCT ID: NCT01951079 Not yet recruiting - Hypotension Clinical Trials

Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy

Start date: November 2013
Phase: Phase 3
Study type: Interventional

In second trimester abortion above 22 weeks the investigators usually inject intra-cardiac Kcl for feticide. Digoxin intra-amniotic injection has been described in the literature in doses of 1-1.5 mg. with a success rate of about 80%, and up to 24 weeks. Our aim in this study is to investigate the safety and success rate of 1.5-2 mg. digoxin, intra-amniotic up to 30 weeks pregnancy .

NCT ID: NCT01950858 Recruiting - Clinical trials for Spontaneous Osteonecrosis of the Knee

Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee

Start date: May 2012
Phase: Phase 1
Study type: Interventional

safety and efficacy of Hyper Baric Oxygen (HBO) in patients presenting with spontaneous osteonecrosis of the knee

NCT ID: NCT01950819 Completed - Hemodialysis Clinical Trials

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

TRANSFORM
Start date: December 3, 2013
Phase: Phase 4
Study type: Interventional

This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.

NCT ID: NCT01949129 Recruiting - Clinical trials for Acute Lymphoblastic Leukaemia

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Start date: April 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.

NCT ID: NCT01948830 Completed - Clinical trials for Age-related Macular Degeneration

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

TREND
Start date: December 2013
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration

NCT ID: NCT01946828 Not yet recruiting - Pupil Dilation Clinical Trials

Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)

TP 7601-CL
Start date: October 2013
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to evaluate the FIM optimal configuration and confirm the safety and performance/efficacy of the FIM when exposed to a larger and more varied population of users.

NCT ID: NCT01946204 Active, not recruiting - Prostatic Neoplasms Clinical Trials

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

SPARTAN
Start date: October 14, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

NCT ID: NCT01945775 Completed - Breast Neoplasms Clinical Trials

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

EMBRACA
Start date: October 14, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.

NCT ID: NCT01945723 Recruiting - Healthy Clinical Trials

Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers

Start date: September 2013
Phase: N/A
Study type: Observational

Tissue characterization will be performed, from different regions of the gastrointestinal tract in healthy volunteers.